Table 3.
Drug versus non-drug | From 2001 versus before 2001 | Per increase of 1 unit in impact factor | |
---|---|---|---|
Reporting of between-group comparisons | 2.39 (0.46 to 12.50) (0.30) | 2.73 (0.63 to 11.90) (0.18) | 1.19 (0.95 to 1.49) (0.14) |
Primary outcome reported | 8.15 (3.16 to 21.03) (< 0.001) | 8.46 (3.18 to 22.49) (< 0.001) | 1.06 (1.01 to 1.11) (0.010) |
Primary outcome is only one measure | 4.19 (1.68 to 10.46) (0.002) | 5.81 (2.17 to 15.59) (< 0.001) | 1.04 (1.01 to 1.08) (0.018) |
No statistical comparison of baseline characteristics | 2.48 (1.11 to 5.56) (0.027) | 0.97 (0.46 to 2.03) (0.93) | 1.0 2 (0.98 to 1.06) (0.30) |
Reporting of handling of missing data | 1.79 (0.74 to 4.32) (0.20) | 2.47 (1.00 to 6.10) (0.049) | 1.03 (1.00 to 1.06) (0.07) |
Intention-to-treat analysis reported | 2.88 (1.39 to 5.99) (0.005) | 2.02 (0.99 to 4.15) (0.055) | 1.03 (0.99 to 1.06) (0.11) |
Reporting of P values and 95% CI (n) | 1.85 (0.81 to 4.24) (0.15) | 1.83 (0.79 to 4.22) (0.16) | 1.07 (1.03 to 1.12) (< 0.001) |
Data are odds ratios (95% CI) (P value)